Immuneering (IMRX) Common Equity (2020 - 2026)
Immuneering (IMRX) reported Common Equity of $168.68 million for Q3 2026, down 26.0% from $227.98 million a year earlier and down 11.6% from the prior quarter.
Powered by 
Analysis
Immuneering (IMRX) Common Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, Immuneering posted Common Equity of $218.48 million, up 427.9% from FY2024.
- By year, Common Equity came in at $41.39 million in FY2024 (-54.3%), $90.58 million in FY2023 (-17.5%), $109.85 million in FY2022 (-29.6%) and $155.98 million in FY2021.
- The Q3 2026 figure ranks as the lowest quarterly Common Equity since Q2 2025.
- Year over year, Common Equity gained in four of the last eight quarters, with growth averaging 186.5%.
- The high point for year-over-year Common Equity in five years was Q2 2026 (growth of 559.2%); the low point was Q2 2025 (a decline of 56.4%).
- Per Business Quant data, the three quarters before Q3 2026 came in at $190.74 million (Q2 2026), $206.52 million (Q1 2026) and $218.48 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 40.27 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | -4.58 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 44.95 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 14.35 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 13.04 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 89.30 Bn |
| 10 | Immuneering | 246.36 Mn | -378.47 Mn | - | 168.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 168.68 Mn |
| Jun 30, 2026 | 190.74 Mn |
| Mar 31, 2026 | 206.52 Mn |
| Dec 31, 2025 | 218.48 Mn |
| Sep 30, 2025 | 227.98 Mn |
| Jun 30, 2025 | 28.94 Mn |
| Mar 31, 2025 | 41.84 Mn |
| Dec 31, 2024 | 41.39 Mn |
| Sep 30, 2024 | 57.72 Mn |
| Jun 30, 2024 | 66.31 Mn |
| Mar 31, 2024 | 78.72 Mn |
| Dec 31, 2023 | 90.58 Mn |
| Sep 30, 2023 | 104.02 Mn |
| Jun 30, 2023 | 115.10 Mn |
| Mar 31, 2023 | 97.79 Mn |
| Dec 31, 2022 | 109.85 Mn |
| Sep 30, 2022 | 121.89 Mn |
| Jun 30, 2022 | 133.59 Mn |
| Mar 31, 2022 | 144.06 Mn |
| Dec 31, 2021 | 155.98 Mn |
API Access
Immuneering Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=IMRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "IMRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=IMRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();